American journal of clinical oncology

1537-453X4022017AprAmerican journal of clinical oncologyAm J Clin OncolLate Toxicity and Outcomes in High-risk Prostate Cancer Patients Treated With Hypofractionated IMRT and Long-term Androgen Suppression Treatment.200206200-20610.1097/COC.0000000000000133To assess late toxicity and outcomes in high-risk prostate cancer patients treated with hypofractionated radiation treatment with androgen suppression therapy.Sixty high-risk prostate cancer patients were enrolled. IMRT prescription was 68 Gy/25 fractions (2.7 Gy/fraction) to the prostate and proximal seminal vesicles (SV). The pelvic lymph nodes (PLN) and distal SV concurrently received 45 Gy/25 fractions (1.8 Gy/fraction). The patients were treated with helical TomoTherapy-based IMRT and underwent daily megavoltage CT image-guided verification before each treatment. RTOG Toxicity scores were recorded for a 5-year period.Sixty patients completed RT with median follow-up of 63 months (range, 7 to 80 mo).At 5 years follow-up timepoint: Grade (G)2 and G3 late genitourinary toxicity was experienced in 7 (17.0%) and 1 (2.44%), respectively; gastrointestinal G2 as highest toxicity recorded in only 1 (2.44%) patient. There was no G3 gastrointestinal toxicity recorded at this timepoint.With 63-month median follow-up (mean of 65.41±1.72 mo), the 5-year overall survival was 86.67%; 5 years freedom from biochemical failure was 91.67% and freedom from clinical failure was 96.67%.Dose escalation and hypofractionated radiation treatment with IMRT treating the prostate and proximal SV concurrently with the pelvic lymph nodes and distal SV and long-term androgen suppression therapy is well tolerated with respect to acute and late toxicity with 5-year actuarial overall survival 86.67%, freedom from biochemical failure 91.38%, and freedom from clinical failure 96.67%. Longer follow-up will provide more information on 10-year survival outcomes.PervezNadeemNDivisions of *Radiation Oncology ∥Medical Physics ¶Division of Experimental Oncology, Department of Oncology, Cross Cancer Institute, Edmonton, AB †Department of Radiation Oncology, Cancer Care, Eastern Health, St Johns, NF ‡Radiation Oncology, Saskatoon Cancer Centre, Saskatoon, SK, Canada §Radiation Oncology, UPMC Beacon Hospital, Dublin, Republic of Ireland.BoychakAlexADrodgeClaudia SCSYeeDonDLeDucDMurthaAlbertAParliamentMatthewMAmanieJohnJMihaiAlinaAFieldColinCMackenzieMarcMGhoshSunitaSFalloneGinoGPearceyRobertRengClinical Trial, Phase IIJournal Article

1537-453X3922016AprAmerican journal of clinical oncologyAm J Clin OncolA Phase I Study of Tomotherapy in Patients With Primary Benign and Low-grade Brain Tumors: Late Toxicity and Quality of Life.160166160-610.1097/COC.0000000000000034To evaluate longitudinal quality of life and late neurotoxicity (>12 mo) of tomotherapy in patients with primary benign and low-grade brain tumors.Between January 2006 and October 2009, 49 patients with brain tumors were treated with tomotherapy at 2 radiotherapy centers in Canada. The median age of the patients was 51.0 years (range, 21 to 74 y); there were 21 men (42.86%) and 28 women (57.14%). All 49 patients had an initial Karnofsky performance score ≥70. One patient (2.04%) received 45 Gy in 25 fractions, 27 patients (55.10%) received 50.4 Gy in 28 fractions, 15 patients (30.6%) received 54 Gy in 30 fractions, and 5 patients (10.2%) received 60 Gy in 30 fractions. A total of 47 patients were analyzed for late toxicity and outcomes.Changes in the Karnofsky Performance Status of the patients did not reach statistical significance (P>0.05). The majority of the quality of life parameters that reached a statistically significant level (P<0.05) of change at 2 years were changes toward improvement (drowsiness, itchy skin, emotional functioning, fatigue, nausea, and appetite). Statistically significant (P<0.05) interval deterioration in physical, role, and social functioning was observed. Actuarial overall survival at 5 years was 91.6%; disease-free survival at 5 years was 86.6%.IMRT helical tomotherapy is well tolerated, without statistically significant constitutional and late neurotoxicity up to the 2-year mark.BoychakAlexA*Department of Radiation Oncology, Cross Cancer Institute, Edmonton, AB †Department of Radiation Oncology, London Health Sciences Centre, London, ON ‡Department of Radiation Oncology, Montreal General Hospital, McGill, QC, Canada.BaumanGlenGFisherBarbaraBAbdulkarimBassamBAmanieJohnJFultonDorcasDMurthaAlbertAPatelSamirSUrtasunRaulRGhoshSunitaSRoaWilson HWHengClinical Trial, Phase IJournal ArticleResearch Support, Non-U.S. Gov't

Publications by authors named "Alex Boychak"

Late Toxicity and Outcomes in High-risk Prostate Cancer Patients Treated With Hypofractionated IMRT and Long-term Androgen Suppression Treatment.

A Phase I Study of Tomotherapy in Patients With Primary Benign and Low-grade Brain Tumors: Late Toxicity and Quality of Life.